ACT-A Updates

Member State COVID-19 Information Session

24 June 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis
ACT-A – Updates & Events

1. ACT-A Financing & Advocacy - recent events

2. COVAX – new supply forecast issued (23 June)

3. ACT-A Strategic Review – in planning (Jul-Sep)

4. Special ACT-A Council Briefing of WHO Member States (6 Jul)

5. Next week & beyond
5 major ACT-A events of past 3 weeks

*Emphasis: equity for Vaccines, tests, treatments & PPE*

- **G20/EC Global Health Summit** (21 May)
- **IMF “Proposal to end the Pandemic”** (21 May & 1 Jun)
- **World Health Assembly incl. IPPPR** (24 May – 1 Jun)
- **Gavi COVAX AMC Summit** (2 June)
- **G7 Summit** (11-13 June)
G7 Leaders’ Summit Communique
Reaffirmed crucial role of ACT-A & announced dose-sharing

“We reaffirm our support for all pillars of the ACT-A across, treatments, tests and strengthening public health systems as well as vaccines.”

G7 main ACT-A/COVAX outcomes

- 870m¹ ‘donated doses’ (>500 m of which additional)
- primarily through COVAX
- >1/2 of these doses in 2021

1. Includes contributions announced for Carbis Bay: US - 500m doses, of which 200m by end 2021; UK - 100m doses, of which 30m by end 2021. France - 30m by end 2021 (+30m already committed, total 60m); Canada - 13m doses; Australia - >20m doses; Republic of Korea - $100m in 2021, equivalent to 18m doses. Commitment to a further $100m vaccines in 2022.
2. For Gavi AMC: USD 100m in 2021 and USD 100m in 2022

Source: Carbis Bay G7 summit communiqué; UK PM Cabinet
COVAX: new supply forecast issued 23 June

There are still substantial risks to projected supply. Deep dive with Gavi next week. A new commitment of manufacturers & contracting & producing countries vital!
Given the ongoing pandemic and need for more equitable access to COVID-19 tools, stakeholders have proposed a strategic review of ACT-Accelerator to inform decision-making about its current operating model & potential role beyond the 1st quarter of 2022.
ACT-A Strategic Review: status of planning

Objectives/dimensions:
1. results against the 2 major ACT-A objectives (acceleration & equity)
2. impact of ACT-A construct & operating model
3. impact of ACT-A financing (inc. pledges, funding rec. & exp).
4. impact of broader ecosystem
5. recommendations for current ACT-A & potential role beyond Q1 2022

Management arrangements:
- Sponsors: invite the 3 WHO Special Envoys for ACT-A (current & Emeritus)
- Reference group: co-hosts, co-convening agencies, council, industry, CSO & Hub reps
- Implementation: external firm with no role in ACT-A

Timeline: (i) targeted RFP in June (ii) contract firm & initiate in Jul (iii) report in Sept

Next steps: share concept note & engage further during inception phase
Special ACT-A Facilitation Council Briefing of WHO Member States
6 July 2021, 12.30 -15.00 (CEST)

Agenda

- current vaccines coverage, COVAX vaccine supply outlook & urgent needs
- most urgent needs & funding requirements for COVID-19 tests, treatments & PPE
- updates on:
  - ACT-A Strategic Review
  - ACT-A Quarterly Impact Report
  - Health Systems Connector workplan
  - Plans for the 7th Council
ACT-A & MS COVID-19 Briefings

Next week:

Interim & Phase 2 allocation criteria for COVAX

COVAX Supply Forecast & risk mitigation (with Gavi)

mRNA Tech Transfer Hub

Upcoming:

Health Systems Connector nearterm workplan (Jul-Dec 2021)